Skip to content
Multiple Sclerosis News Today logo Newsletter
Newsletter
  • About MS
    Multiple sclerosis overview
    • Types of MS
    • Causes and risk factors
    • Symptoms
    • Diagnosis
    • Living with MS
    Treatments options for MS
    • Approved treatments
    • Experimental treatments
    Clinical Trials
    • What are clinical trials?
    • Types of clinical trials
    • How do clinical trials work?
    • Traditional vs. remote vs. hybrid clinical trials
    • FAQs about clinical trials
  • Featured Topics
    Newly diagnosed guide
    • MS and employment
    • Next steps after an MS diagnosis
    • MS caregivers guide
    • MS healthcare team
    • Perspectives on MS diagnosis
    • MS treatment explainer
    • Questions to ask your doctor
    • Guidelines for MS diagnosis
    • Physical activity and quality of life
    • Foods to eat and avoid
    • View all
    MS pathways
    • MS and sleep
    • Videos: Worth the talk
    • Managing RRMS
    • Changing MS therapy
    • Mental health and MS
    • MS spasticity stretches
    • MS apps and tools
    • Energy levels and MS
    • MS and eating
    Living strong
    • Stress and MS
    • MS and exercise
    • MS safe home tips
    • MS in women
    • Talking to your doctor
    • Recognizing MS symptoms
    • MS and restless leg syndrome
    Resources
    • MS hug
    • MS and heat
    • Cannabis and MS
    • Lesions and MS
    • Myelin's role in MS
    • Epstein-Barr virus and MS
    • Stem cell therapy for MS
    • MS prognosis and life expectancy
    • MS and mental health
    Expert voices
    • Exercise
    • Pain management
    • Cannabis use
    • Diet and nutrition
    • Financial planning
    • Managing fatigue
    • Sleeping well
    • More
  • News
  • Columns
    Authentically Human – Desiree Lama
    Balancing Grit and Grace – Ahna Crum
    Chairborne — Ben Hofmeister
    Delicate Balance – Leigh Anne Nelson
    Rhythms and Routines – Susan Payrovi, MD
    Archived Columns
    • A Life in Letters — Jamie Hughes
    • DISabled to ENabled — Jessie Ace
    • Dive to Fight MS – Mike Parker
    • Fall Down, Get Up Again — John Connor
    • Goldilochs — Stephen De Marzo
    • Patiently Awakened — Teresa Wright-Johnson
    • The MS Wire — Ed Tobias
    • Silver Linings — Jennifer Powell
    In memoriam
    • Through the Looking Glass — Beth Shorthouse-Ullah
  • Forums
  • Video & Podcasts
    Get Tough on Multiple Sclerosis Video Series
    Get Tough on Multiple Sclerosis Podcast
    The Multiple Sclerosis Podcast
  • Advocacy partners
  • What can we help you find today?

November 4, 2024 News by Esteban Domínguez Cerezo, MS

Dosing begins in early clinical trial of Lucid-MS to protect myelin sheath

A first group of healthy adults has been dosed in a Phase 1 safety and tolerability trial of Lucid-21-302, a potential myelin-protective oral treatment for multiple sclerosis (MS), regardless of disease type. These initial volunteers will serve as the trial’s sentinels, an occasional study feature allowing for a…

April 3, 2024 News by Patricia Inacio, PhD

Clinical trial to test multiple Lucid-MS doses in healthy volunteers

FSD Pharma has entered an agreement to launch a Phase 1 clinical trial that will test multiple ascending doses of Lucid-21-302 — an oral treatment candidate commonly known as Lucid-MS, for all types of multiple sclerosis (MS) — in healthy volunteers. The company’s subsidiary Huge Biopharma Australia established…

September 25, 2023 News by Patricia Inacio, PhD

Data: Lucid-MS seen to be safe, well tolerated in healthy volunteers

FSD Pharma’s Lucid-21-302 — an oral treatment candidate known as Lucid-MS, for all types of multiple sclerosis (MS) — was found safe and well tolerated across multiple doses in healthy volunteers, according to interim data from a Phase 1 clinical trial. The newly released data are from the…

May 15, 2023 News by Margarida Maia, PhD

1st group of healthy volunteers dosed in Phase 1 trial of ‘Lucid-MS’

FSD Pharma has completed dosing in the first group of healthy volunteers enrolled in its Phase 1 clinical trial testing Lucid-21-302, an oral medication candidate for all types of multiple sclerosis (MS). The medication, also known as Lucid-MS, was first given to a sentinel subject — one…

April 20, 2023 News by Margarida Maia, PhD

First participant completes dosing in Phase 1 Lucid-MS trial

The first participant has completed dosing in a Phase 1 clinical trial testing FSD Pharma‘s Lucid-21-302, an experimental oral medication for all types of multiple sclerosis (MS), in healthy volunteers. After receiving a green light from Health Canada to launch the first-in-human trial, the company began by…

February 9, 2023 News by Andrea Lobo, PhD

Health Canada clears Phase 1 trial of Lucid-MS in healthy volunteers

FSD Pharma will soon launch a first-in-human trial testing Lucid-21-302, known as Lucid-MS — its novel chemical treatment for multiple sclerosis (MS) — in healthy volunteers. Health Canada has cleared the company to initiate a Phase 1 clinical trial of the investigational therapy, FSD Pharma announced in a…

January 18, 2023 News by Marisa Wexler, MS

FSD Asking to Open Trial of Lucid-MS, Myelin-protecting Therapy

FSD Pharma has submitted an application to Health Canada asking to start a Phase 1 clinical trial of Lucid-MS, the company’s experimental and myelin-protective oral therapy for people with multiple sclerosis (MS). The trial will not involve patients and is designed to investigate the safety and tolerability of…

December 6, 2021 News by Patricia Inacio, PhD

Lucid-MS Restores Motor Function in Mouse Model, Company Says

Lucid-MS, a new chemical molecule being developed by FSD Pharma for the treatment of multiple sclerosis (MS), has shown the ability to restore motor function in an animal model of the disease, the company announced. After about 50 days of treatment, animals receiving Lucid-MS showed a marked decrease…

Recent Posts

  • B-cell levels can predict PIRA risk in relapsing MS patients on Ocrevus
  • Worsening disability tied to loss of bone mineral density in MS
  • With multiple sclerosis, it’s OK to rant sometimes


Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Bionews, Inc.

3 W Garden St
Suite 700
Pensacola, FL 32502
Website: bionews.com
Email: [email protected]
Phone: 1-800-936-1363

  • About Us
  • Leadership
  • Our Culture
  • Editorial Policy
  • Advertising Policy
  • Corrections Policy
  • Terms of Service
  • Privacy Policy
  • Careers
  • Contact Us
Disclaimer

This site is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Copyright © 2013-2025 All rights reserved.